Tenzing Acquisition completed the merger with Reviva Pharmaceuticals in a $62m deal.

Tenzing Acquisition, a special purpose acquisition company incorporated in the British Virgin Islands, completed the merger with Reviva Pharmaceuticals, a California-based clinical stage pharmaceutical company, in a $62m deal. "The execution of the merger agreement presents an important milestone and represents a unique opportunity to finance and advance the clinical development of Reviva's innovative therapies, which may improve treatment options for neuropsychiatric and respiratory diseases with high unmet medical needs," Laxminarayan Bhat, Reviva Founder, President and CEO.